Furthermore, another Phase III clinical trial is underway in gastric cancer to assess the efficacy and safety of onartuzumab when administered in combination with mFOLFOX6 for treating metastatic HER2– and c-MET+ gastroesophageal cancer (78). The gene discussed is MET; the disease is gastric cancer.